Surprisingly, CD73+ Teff displayed increased capacity to produce IFN-γ in RA patients (Figure 4C) and to co-produce IFN-γ and IL-17A after MTX treatment in both RA (Figure 4C) and PsA patients (Figure 4D). Here, IL17A is linked to rheumatoid arthritis.